JBPH.F Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.29 |
| 52 Week High | HK$0.54 |
| 52 Week Low | HK$0.29 |
| Beta | 0.56 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| JBPH.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | 0.7% |
| 1Y | n/a | 8.8% | 21.5% |
Return vs Industry: Insufficient data to determine how JBPH.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how JBPH.F performed against the US Market.
Price Volatility
| JBPH.F volatility | |
|---|---|
| JBPH.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: JBPH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine JBPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 301 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company’s lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-(L)1 resistant cancer; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
| JBPH.F fundamental statistics | |
|---|---|
| Market cap | US$189.75m |
| Earnings (TTM) | -US$49.71m |
| Revenue (TTM) | US$8.79m |
21.6x
P/S Ratio-3.8x
P/E RatioIs JBPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JBPH.F income statement (TTM) | |
|---|---|
| Revenue | CN¥63.52m |
| Cost of Revenue | CN¥60.32m |
| Gross Profit | CN¥3.20m |
| Other Expenses | CN¥362.32m |
| Earnings | -CN¥359.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 5.04% |
| Net Profit Margin | -565.36% |
| Debt/Equity Ratio | 6.9% |
How did JBPH.F perform over the long term?
See historical performance and comparison